Article thumbnail

The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias

By Flora Tzifi, Christina Economopoulou, Dimitrios Gourgiotis, Alexandros Ardavanis, Sotirios Papageorgiou and Andreas Scorilas


The disturbance of apoptosis molecular signaling pathways is involved in carcinogenesis. BCL2 family of proteins is the hallmark of apoptosis regulation. In the last decade, new members of BCL2 gene family were discovered and cloned and were found to be differentially expressed in many types of cancer. BCL2 protein family, through its role in regulation of apoptotic pathways, is possibly related to cancer pathophysiology and resistance to conventional chemotherapy. It is well known that leukemias are haematopoietic malignancies characterized by biological diversity, varied cytogenetics, different immunophenotype profiles, and diverse outcome. Current research focuses on the prognostic impact and specific role of these proteins in the pathogenesis of leukemias. The understanding of the molecular pathways that participate in the biology of leukemias may lead to the design of new therapies which may improve patients' survival. In the present paper, we describe current knowledge on the role of BCL2 apoptosis regulator proteins in acute and chronic leukemias

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). A .B .W e r n e r ,S .W .G .T a i t ,E .D eV r i e s ,E .E l d e r i n g ,a n dJ . Borst, “Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens,”
  2. (2005). A .C immino ,G .A .C alin,M.F ab b rie tal. ,“ miR - 15andmiR -16 induce apoptosis by targeting
  3. A .L a z a r i d o u ,C .M i r a x t s i ,J .K o r a n t z i s ,N .E l e f t h e r i a d i s ,a n d
  4. (2004). A .M .P e t r o s ,E .T .O l e j n i c z a k ,a n dS .W .F e s i k ,“ S t r u c t u r a l biology of the Bcl-2 family of proteins,”
  5. (2002). a d e r l ,M .J .K e a t i n g ,K .A .D oe ta l . ,“ E x p r e s s i o np r o fi l eo f 11 proteins and their prognostic significancein patients with chronic lymphocytic leukemia (CLL),”Leukemia,
  6. a n g ,X .M .Y i n ,D .T .C h a o ,C .L .M i l l i m a n ,a n dS .J . Korsmeyer, “BID: a novel BH3 domain-only death agonist,” Genesand Development,vol.10,no.
  7. (2008). A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells,”
  8. (2001). A rnoetal.,“Micr oen vironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NFkappaB, c-Myc, and pRb pathways,”
  9. (2004). A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia
  10. (2008). ABT-263: a potent and orally bioavailable
  11. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT737 in vitro and in vivo,”
  12. (1998). Akar et al., “Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses,”
  13. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a prosurvival signal: the therapeutic potential of Akt inhibition,”
  14. (2005). Albitar et al., “Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia,”
  15. (2006). Alterations in mRNA expression of apoptosisr e l a t e dg e n e sB
  16. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours,”
  17. (2003). and Z.Estrov, “Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia,”
  18. (2004). Antiapoptotic microenvironment of acute myeloid leukemia,”
  19. (1995). Antisense oligodeoxyribonucleotide downregulation of bcl-2 gene expression inhibits growth of the low-gradenon-Hodgkin’slymphomacell lineWSU-FSCCL,”
  20. (2004). Apoptosis mechanisms: implications for cancer drug discovery,” Oncology,
  21. (2004). Assessment of bcl-2 expression ass modulator of Fas mediated apoptosis in acute leukemia,” Hematology,v o l .9 ,n o .2 ,p p .
  22. (2000). B e l l o w s ,B .N .C h a u ,L .P e r c y ,Y .L a z e b n i k
  23. (2000). BAX and PKCalpha modulate the prognostic impact of BCL2 expression
  24. (1998). Bax cleavage is mediated by calpain during drug-induced apoptosis,”
  25. (1997). Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase,”
  26. (2005). Bcl-2 antisense therapy in B-cell malignancies,”
  27. (1996). Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinicaloutcome,”
  28. (2006). BCL-2 in the crosshairs:tipping the balance of life and death,”
  29. (1996). bcl-2, Bax and p53 expression in BCLL in relation to in vitro survival and clinical progression,”
  30. (1992). Bcl-2: an antidote to programmed cell death,”
  31. (2005). Bcl-X(L) specifically activates Bak to induce swelling and restructuring of the endoplasmic reticulum,” J o u r n a lo fC e l lB i o l o g y ,
  32. (2008). BCL2 expression inchroniclymphocytic leukemia:lackofassociationwiththe BCL2 938C>A promoter single nucleotide polymorphism,”
  33. (2006). BCL2 family of apoptosisrelated genes: functions and clinical implications in cancer,”Advances
  34. (2005). Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia,”
  35. (2003). Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of
  36. Chipuk et al., “BH3 domains of BH3-only proteins differentially regulate Baxmediated mitochondrial membrane permeabilization both directly andindirectly,”MolecularCell,vol.17,no.4,pp.525– 535,
  37. (2007). Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737,”
  38. (2003). Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12,”
  39. (1996). Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia,”
  40. (1999). Clinical signifi-cance ofCD95, Bcl-2 and Baxexpression and CD95 function in adult de novo acute myeloid leukemia in context of Pglycoprotein function, maturation stage, and cytogenetics,”
  41. (2001). Combinedexpressionofp53,Bcl-2,andp21WAF-1proteins in lung cancer and premalignant lesions: association with clinical characteristics,”
  42. (1997). Comparative flow cytometric evaluation of
  43. (2000). Cytogenetic abnormalities in chronic lymphocytic leukemia,”Folia
  44. (1993). D.Campana,E.Coustan-Smith,A.Manabeetal.,“Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of
  45. (2010). Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood,”
  46. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis,”
  47. (2003). Diversity in the mechanisms of neuronal cell death,”
  48. (2001). Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors,”
  49. (1998). Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with
  50. (1998). Elevated plasmalevels of interleukin-1 receptor antagonist are associated with decreased cellular
  51. (1988). Enforced expression of the c-myc oncogene inhibitscell differentiationby precluding entry into adistinct predifferentiation state
  52. (2007). Enhanced antileukemic activity of the novel complex 2,5-dihydroxybenzoate molybdenum(VI) against 2,5-dihydroxybenzoate, polyoxometalate of Mo(VI),
  53. Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine) 2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines,”
  54. (2004). Expression analysis of BCL2L12, a new member of apoptosis-related genes,
  55. (1996). Expression of BCL2 proto-oncogene in adult acute lymphoblastic leukemia,”
  56. (2003). Expression of BCL2L12, a new member of apoptosis-related genes,
  57. (2006). F a r i a ,M .Y a m a m o t o ,R .M .D .F a r i a ,J .K e r b a u y ,a n d
  58. (2004). Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc,”
  59. (2005). Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin’s lymphoma,”
  60. (2003). G.Marcucci,J.C.Byrd,G.Daietal.,“Phase1andpharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia,”
  61. (2000). H.WalczakandP.H.Krammer,“TheCD95(APO-1/Fas)and the TRAIL (APO-2L) apoptosis systems,”
  62. (2000). High bax expression is a good prognostic indicator in acute myeloid leukaemia,”
  63. (2002). High BcrAbl expression prevents the translocation of Bax and Bad to the mitochondrion,”Leukemia, vol.16,no.9,
  64. (1998). High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia,”
  65. (2005). High expression of bfl-1 contributes to the apoptosis resistant phenotype
  66. How cells die: apoptosis pathways,”
  67. (2005). I.Wojcik,M.Szybka,E.Golanskaetal.,“Abnormalitiesofthe P53, MDM2, BCL2 and BAX genes in acute leukemias,”
  68. (2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemiceffects ofimatinibandmcl-1antisenseoligonucleotides,”
  69. (1999). Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia,”
  70. (2000). Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation,”
  71. (1990). Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia,”
  72. (2004). Interleukin-1beta maintains an apoptosis-resistant phenotype in theblastcells ofacute myeloidleukaemiaviamultiple pathways,”
  73. (1999). J i a n g ,X .Z h a n ge ta l . ,“ E x p r e s s i o no fB c l -2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid,” Leukemia,v o l .
  74. (1999). M.Shikami,H.Miwa,K.Nishiietal.,“LowBCL-2expression in acute leukemia with t(8;21) chromosomal abnormality,”
  75. (2004). Mcl-1 and Bcl-2/Bax ratio are associatedwith treatment responsebut not with Rai stage in B-cell chronic lymphocytic leukemia,”American
  76. (2009). Mcl-1 is a potential therapeutic target in multiple types of cancer,”
  77. (2006). Mcl-1: a highly regulated cell death and survival controller,”
  78. (2008). Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines:
  79. (2008). MiR-15a and miR-16-1 cluster functions in human leukemia,”
  80. (1998). Mitochondria and apoptosis,”
  81. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond,”
  82. (2010). Mitochondrial signalingin cell death via the
  83. (2000). Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells,”
  84. (2001). Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved
  85. (2009). Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, includingthenewmemberBCL2L12,”Annals of theNewYork
  86. (2004). mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin,” Biological Chemistry,v o l .
  87. (2002). New drugs in acute myeloid leukemia,”
  88. (1999). o c h l i t z ,A .L o h r i ,M .B a c c h ie ta l . ,“ A x le x p r e s s i o ni s associated with adverse prognosis and with expression of
  89. (1998). o l i c a ,A .D a t t i l o ,C .G i u l i n o ,D .L e v a t o ,a n dL .L e v a t o , “Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease,”
  90. (2007). Okvist et al., “Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia,”
  91. (2007). P i c k e r i n g ,S .D eM e l ,M .L e ee ta l . ,“ P h a r m a c o l o g i c a l inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells,” Oncogene,v o l .2 6 ,n o .8 ,p p .
  92. (2003). P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia,”
  93. (2005). Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity,”
  94. (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia,”
  95. (2006). Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities,”
  96. (2005). Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia
  97. (2004). Prognostic significance of a short sequence insertion in the MCL1 promoter in chronic lymphocytic leukemia,”
  98. (2004). Quantitative analysis of bcl-2 expression in normaland leukemic human
  99. (2000). Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo,”
  100. (2009). Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells,”
  101. (2004). Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors,”
  102. (2002). S.Cory andJ.M.Adams,“The BCL2family:regulators ofthe cellular life-or-death switch,”
  103. (2002). SahuandB .R .D as,“ P r ognost icsignific anc eofp
  104. (2007). Scorilas,“Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer,”
  105. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 notBCL-X(L),”
  106. (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid,”
  107. (1997). STATs and gene regulation,” Science,v o l .
  108. (2002). Synergistic induction of apoptosis by simultaneous disruption of the
  109. (2006). Synthesis and secondary structure
  110. (2010). T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation,”
  111. (2002). T.Kohler,C.Schill,M.W.Deiningeretal.,“Highbadandbax mRNA expression correlate with negative outcome in acute myeloid leukemia
  112. (1996). The AML1/ETO fusion protein activates transcription of
  113. (1998). The Bcl-2 protein family: arbiters of cell survival,”
  114. (2008). The BCL-2 protein family: opposing activities that mediate cell death,”
  115. (1997). The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis,”
  116. (2009). The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia,”
  117. (2006). The expressionof70apoptosisgenesinrelationtolineage,genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia,”
  118. (2006). The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia,” Leukemia,v o l .2 0 ,n o .1 ,p p .
  119. (1999). The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics,”
  120. (1119). The study for loss of bcl-xs expression as a prognostic factor in acute myeloid leukemia,”Leukemia Research,vol.26,no.12,pp.
  121. (2000). The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf,” Molecular and Cellular Biology,
  122. (1985). The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes
  123. (2000). TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation,” J o u r n a lo fO r a lP a t h o l o g ya n dM e d i c i n e ,
  124. (2006). Topotecan and methotrexate alter expression of the apoptosis-related genes
  125. (2006). Treatment of MCF-7 cells with taxol and etoposide induces distinct
  126. (2007). u c k e l ,U .H .F r e y ,M .B a ue ta l . ,“ A s s o c i a t i o no fan o v e l regulatory polymorphism (−938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia,”
  127. (1998). u o ,I .B u d i h a r d j o ,H .Z o u ,C .S l a u g h t e r ,a n dX .W a n g , “Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors,”
  128. (2002). Y.Zhu,G.Y.Yang,B.Ahlemeyeretal.,“Transforminggrowth factor-beta 1 increases bad phosphorylation and protects neurons againstdamage,”
  129. (2003). Z i n k e l ,C .C .O n g ,D .O .F e r g u s o ne ta l . ,“ P r o a p o p t o t i c BID is required for myeloidhomeostasisand tumor suppression,”